Analysis of progression-free survival ( PFS ) as the primary endpoint in advanced epithelial ovarian , fallopian tube , and primary peritoneal cancer ( AEOC ) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments .